Prof. Axel Grothey
Axel Grothey M. D., is a consultant in the Division of Medical Oncology, Department of Oncology, at Mayo Clinic. He holds the academic rank of professor of oncology and has teaching/examining privileges in Clinical & Translational Science at Mayo Graduate School. Dr. Grothey received his medical degree at Ruhr-Universitat Bochum, Germany, and completed residencies at West-German Tumorcenter and the Institute of Pathology at the University of Essen and a residency and fellowship at the University of Bochum. He also completed a research fellowship at MD Cancer Center at the University of Texas.
Dr. Grothey’s clinical interests focus on gastrointestinal cancers, in particular, colorectal cancer, anti-angiogenesis, signal transduction inhibitors, and clinical trial design and statistics. As a consultant and investigator, his research has been funded by the National Cancer Institute (NCI) and the National Institutes of Health, among other organizations. He currently chairs the NCI colon cancer task force, and serves as vice-chair of the gastrointestinal cancer committee of the Alliance for Clinical Trials in Oncology, an NCI-funded cooperative group. He is also chair of the Academic and Community Cancer Research United (ACCRU) international research network.
Dr. Grothey serves in journal review and editorial activities for numerous medical journals and is editor for Clinical Colorectal Cancer, Emerging Cancer Therapeutics, OncologySTAT, and Therapeutic Advances in Medical Oncology. In educational activities, he has served as a teacher, and he is a five-time recipient of Teacher of the Year recognition at Mayo Clinic. Dr. Grothey has given numerous international, national and regional presentation, as well as invited and visiting professor presentations. He has co-authored more than 250 articles, books, book chapters, editorials, abstracts and letters.
Prof. Shaji Kumar
Shaji Kumar M. D., received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in Internal Medicine from the All India Institute of Medical Sciences, followed by a residency in Internal Medicine and a fellowship in Hematology/Oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota.
Certified by the American Board of Internal Medicine (ABIM) in internal medicine and medical oncology and an ABIM Diplomate in hematology, Dr. Kumar holds membership in several professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, the American Society of Blood and Marrow Transplantation, the Association of Physicians of India, and the European Hematology Association.
Dr. Kumar has published numerous articles, abstracts, editorials, and letters in the peer-reviewed literature, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also a member of the editorial board for several journals, including American Journal of Hematology, European Journal of Clinical and Medical Oncology and Leukemia.
Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
He is currently the Medical Director for the Cancer Center Clinical Research Office, which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.
Prof. Mohammad Jahanzeb
Mohammad Jahanzeb, MD, FACP, is Professor of Clinical Medicine, Hematology Oncology at University of Miami’s Miller School of Medicine. Dr. Jahanzeb currently serves as the Medical Director of UM Sylvester Deerfield Campus and an Associate Director of Community Outreach for the Sylvester Comprehensive Cancer Center. An international lecturer on issues related to breast and lung cancers, Dr. Jahanzeb has given more than 800 lectures as an invited speaker and has authored or contributed to more than 150 original reports, book chapters, reviews, and abstracts.
Dr. Jahanzeb is board certified in internal medicine with subspecialties in hematology and medical oncology. He received his medical degree with high honors from King Edward Medical College at the University of Punjab in Lahore, Pakistan. Dr. Jahanzeb is a fellow of the American College of Physicians and American College of International Physicians, and belongs to several professional societies including the American Society of Clinical Oncology, American College of Physicians, the American Society of Hematology and the International Association for the Study of Lung Cancer. He is the Chair Elect for QOPI Measures Steering Committee for American Society of Clinical Oncology and he is currently a member of the FLASCO Board of Directors and is Chairman of the Program Committee.
Prof. Damiano Rondelli
Damiano Rondelli M. D. is a Professor of Medicine and Director of Stem Cell Transplant Program at the University of Illinois at Chicago. His clinical research focuses on allogeneic stem cell transplantation. In particular, his interest has been on the use of i.v. busulfan in transplant conditioning regimens; stem cell transplantation in myelofibrosis; and identification of biomarkers of acute and chronic GVHD by flow cytometry. His laboratory focuses on in-vitro and in-vivo models of T cell alloreactivity against hematopoietic stem cells and translational strategies to overcome it.
Dr. Rondelli serves as a member of the International Myeloproliferative Disorders Research Consortium (MPD-RC), funded by an NCI PO1 grant (PI Ronald Hoffman, MD) where he chairs a study using a reduced intensity conditioning regimen in allogeneic stem cell transplantation for patients with myelofibrosis.
Dr. Rondelli has published over 90 full-papers in international peer-reviewed journals including Blood, Leukemia, Biology Blood Marrow Transplantation, and is a co-author of an Italian Hematology textbook. “Lezioni di Ematologia” by Sante Tura et al, Esculapio Bologna, 2003. He is a reviewer of many esteemed journals including Blood, Cancer research, American Journal of Transplantation, etc.
Prof. P. Venugopal
Parameshwaran Venugopal M.D., is a co-director of the lymphoma program and associate director of hematology and stem cell transplantation at the Rush University Medical Center, Chicago. His clinical expertise includes biologic therapy for cancer, cutaneous T-cell lymphoma, leukemias, acute and chronic lymphoma, myelodysplastic syndrome, myelomas, myeloproliferative disorders, and radioimmunotherapy among others.
Prof. Venugopal has been an invited speaker at many medical institutions, both in the United States and abroad. He has authored or co-authored 91 full-length manuscripts, 7 book chapters, and over 240 abstracts. He also serves on the Advisory Board of the Leukemia Society of America.
Prof. John A. Thompson
John A. Thompson, MD, is the Medical Director of the Phase 1 Clinical Trials program and Director of the Melanoma Clinic at the Seattle Cancer Care in Seattle, Washington. He is a professor of medicine at the University of Washington and member of the Fred Hutchinson Cancer Research Center. Dr. Thompson received his medical degree from the University of Alabama and completed his residency in internal medicine and fellowship in medical oncology at the University of Washington. His research interests include the development of immunotherapeutic approaches to cancer treatment.
Dr. Thompson is a member of several medical societies, including the American Society of Clinical Oncology, the American Association for Cancer Research, the Society for Immunotherapy of Cancer and the Kidney Cancer Association. He is a past president of the Washington State Medical Oncology Society. He has authored or co-authored more than 150 articles, appearing in publications such as the Journal of Immunology, Blood, the Journal of Clinical Oncology, and Cancer Research. Dr. Thompson has served as a member of the NCCN Melanoma Panel since its inception, and is currently the Vice-Chair of the committee.
Prof. Farhad Ravandi
Dr. Ravandi is a Professor of Medicine and Chief, Section of Developmental Therapeutics in the Department of Leukemia at The University of Texas (UT) M. D. Anderson Cancer Center in Houston, Texas. Dr. Ravandi earned his medical degree from St. Mary’s Hospital Medical School/Imperial College at the University of London in London, United Kingdom. As part of his postgraduate training, he held residencies in internal medicine at the University of Texas and in hematology at the Baylor College of Medicine, both in Houston, Texas.
He held a clinical fellowship in hematology/oncology followed by a fellowship in blood and marrow transplantation at the UT M. D. Anderson Cancer Center. After fellowship, he was the director of Leukemia program and interim director of the stem cell transplant program at the University of Illinois at Chicago before returning to join the faculty at UT M.D. Anderson Cancer Center. He is interested in the treatment of acute and chronic leukemias and bone marrow failure syndromes.
Dr. Ravandi is board certified in internal medicine, hematology and medical oncology and is a member of the American Society of Clinical Oncology, the American Society of Hematology and the European Society of Hematology.
Dr. Ravandi is the chief editor of Frontiers in Hematology Oncology and a member of editorial boards of Journal of Clinical Oncology, Leukemia, PLoS One, and Leukemia and Lymphoma. He is also a reviewer for journals Blood, Journal of Clinical Oncology, Lancet, Hematologica, Experimental Hematology, Cancer Research, American Journal of Hematology, Leukemia, Cancer, Leukemia and Lymphoma, and Leukemia Research. He is the author or co-author of over 320 articles in peer-reviewed journals.
Prof. Arkadiusz Dudek
Dr. Dudek was recruited to Division of Hematology and Oncology at UIC in 2013 after 15 years of serving in several leadership positions in the Division of Hematology, Oncology, and Transplantation at the Comprehensive Cancer Center of the University of Minnesota. His background includes over 17 years of cancer clinical research experience, over 17 years in clinical management of thoracic, skin, pancreatic, and urologic cancers, and over 12 years in the field of endothelial cell biology, tumor angiogenesis, and cancer immunotherapy.
While at the University of Minnesota, Dr. Dudek served as the Director of the Solid Tumor Oncology Team, the Cancer Experimental Therapeutics Initiative, and the HOT Division Clinical Research Office. He managed a broad range of clinical trials while at the same maintained an active laboratory focused on delivery of cancer gene therapy using endothelial cells. In addition his laboratory performed multiple preclinical drug testing of novel anticancer compounds (MT103, protein kinase C inhibitor MT447, EGF4KDEL) and he was an active member of the Tumor Microenvironment Program with his research focus on tumor angiogenesis.
At UIC, Dr. Dudek is involved in bringing several UI discoveries to clinical testing ( pro-caspase 3 activator PAC-1, Nanomedicine P-SSM-VIP, Mito-spyro, and p19 ARF peptide ). He works closely with inventors to move discoveries through the pre-IND process and develop clinical protocols for first-in-human clinical trials (PAC-1, IGF-Methotrexate). In addition, he builds infrastructure for personalized cancer medicine to perform adaptive clinical trials.
Dr. Heather Wakelee
Dr. Heather Wakelee is an Associate Professor of Medicine at Stanford University in the Division of Oncology where she leads the thoracic medical oncology research program and has authored or co-authored over 100 medical articles on thoracic malignancies. She is the faculty director of the Stanford University Cancer Clinical Trials Office (CCTO). Dr. Wakelee’s focus is on clinical research in thoracic malignancies including lung cancer and thymic malignancies.
Dr. Wakelee has led multiple investigator-initiated protocols and played a central role in clinical trials with bevacizumab and many other anti-angiogenic agents. She is the PI on the multinational E1505 study of adjuvant bevacizumab in NSCLC. She has also run clinical trials of drugs and drug combinations focused on overcoming EGFR and ALK inhibitor resistance, Met inhibitors and novel immune modulatory agents. Additional areas of interest include lung cancer in never-smokers and novel lung cancer biomarkers. She is an active member of the Eastern Cooperative Oncology Group, the International Association for the Study of Lung Cancer, the American Society of Clinical Oncology and the International Thymic Malignancies Interest Group.
Dr. Evan Yu
Evan Y. Yu, M.D., is a medical oncologist specializing in prostate, bladder, and testicular cancer treatment and research. He graduated Alpha Omega Alpha from the University of Washington School of Medicine and his post-doctoral training was at Harvard Medical School. He completed internal medicine residency at the Brigham and Women’s Hospital and oncology fellowship at the Dana-Farber Cancer Institute. He returned to Seattle at the end of 2004 to join the faculty at the University of Washington and Fred Hutchinson Cancer Research Center. He now is an Associate Professor, and he is the director of the Clinical Trials Core for GU malignancies as well as having an integral role in the Pacific Northwest Prostate Cancer SPORE.
Dr. Yu’s research focuses on testing the next wave of novel molecular targeted therapies, with a particular focus on novel molecular imaging with PET to evaluate treatment response in bone metastases to systemic therapies in patients with prostate cancer. In addition to an active clinical practice, he also is the Assistant Fellowship Director and remains very active in student, resident, and fellow education. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle magazine, and Seattle Met magazine. He continues to serve on the National Cancer Institute Genitourinary Cancers Steering Committee.
Dr. Prakash Neupane
Dr. Prakash Neupane is Hematologist Oncologist and Assistant Professor of medicine at The University of Kansas Medical Center. He graduated from Tribhuwan University, Kathmandu Nepal, Completed internal medicine residency and fellowship in Hematology and Oncology. Dr. Neupane has served as Clinical Assistant Professor at Louisiana State University, has spent several years in practice of general hematology and oncology before joining The University of Kansas Medical Center.
Dr. Neupane currently serves as Co-chair of head and neck disease group for clinical research, director of head and neck medical oncology and associate director of hematology oncology fellowship program. Clinical research interest are head and neck oncology and thoracic oncology.
Dr. Brian Samuels
Dr. Brian Samuels graduated with Honors from the Godfrey Huggins School of Medicine at the University of Rhodesia. He completed his internal medicine residency at the Albert Einstein Medical Center in Philadelphia. He also earned the Fellowship of the South African College of Physicians. After residency, he continued his training with a fellowship in Hematology and Oncology at the University of Chicago. He joined the faculty of the University of Chicago, transferring to the University of Illinois as an Associate Professor of Oncology in 1996.
Dr. Samuels is a recognized expert in sarcoma. Dr. Samuels has participated extensively in clinical oncology research and has been an author of over 60 publications and book chapters, 25 in the field of sarcoma. He has presented his research at many national and international oncology meetings. He has been selected by his physician peers for inclusion in the Top Doctors in America publication for all 13 years of its publication and for inclusion in the Top Doctors in Cancer for all 8 years of its publication.
Dr. Binay Shah
Dr. Binay Shah is a hematologist/oncologist and the medical director at the St. Joseph Regional Cancer Center and Blood Institute, Lewiston, Idaho. His practice focuses on management of lymphoma. His research focusses on health services and outcomes. He has published more than 50 papers in prestigious journals.
Dr. Shah has presented his research papers in numerous national and international conferences. He also chaired the International Conference on Advances in Hematologic Malignancies held in Kathmandu, Nepal, last fall.
Dr. Shah is the Founder and President of the Binaytara Foundation. He serves as the President of Idaho Society of Clinical Oncology.
Dr. Arvind Chaudhry
Arvind Chaudhry, MD, PhD is a board certified in Internal Medicine and Medical Oncology, and is the director of Spokane Valley Cancer Center. He received his cancer training at the National Cancer Institute, at the National Institutes of Health in Bethesda, MD, where he completed his fellowship in Hematology and Oncology. Dr Chaudhry also completed a PhD program and doctoral thesis in cancer research at Uppsala University, Uppsala, Sweden.
Dr. Roland Walter
Dr. Roland Walter is currently an Assistant Member in the Clinical Research Division at the Fred Hutchinson Cancer Research Center, an Associate Professor of Medicine in the Division of Hematology/Department of Medicine at the University of Washington (UW) School of Medicine, and an Adjunct Associate Professor in the Department of Epidemiology at the UW, School of Public Health.
Dr. Walter’s research is centered on human acute myeloid leukemia (AML). A primary focus of his laboratory-based translational studies is the development of antigen-specific immunotherapies aimed at eradicating AML cells, including underlying progenitor and stem cell populations. He is particularly interested in the identification of the most suitable target antigen for such therapeutics, and an in-depth understanding of their mechanisms of action and resistance and, consequently, the development of rational strategies that can overcome relevant resistance factors. In clinical studies, Dr. Walter is involved in the early testing of novel drugs and innovative care approaches in patients with AML. Finally, he participates in collaborative projects utilizing large datasets that aim to improve diagnostic and prognostic tools in AML.
Dr. Dinesh Pendharkar
Dinesh Pendharkar, MD,PhD is a consultant Medical Oncology at Asian Institute of Oncology, Mumbai, India. He hold the rank of Program Director Medical Oncology and Visiting Professor RD Gardi Medical College Ujjain. After graduating from Moscow in 1979, he did residency at Tata Memorial Hospital Mumbai and Cancer Research Center Moscow .Afterwards he served at All India Institute of Medical Sciences, New Delhi, Choithram Hospital Indore and Batra Hospital N.Delhi.
Being one of the first private practitioners on the field he pioneered establishment of the speciality. His area of interest include general oncology, professional education and public education. One of his most recognized, clinically impacting research relates to management of hand foot syndrome using urea containing ointment. The concept is use by many clinicians world over in day to day practice. In the field of professional education he has conducted many activities nationally and internationally in various institutions.
He is present Chair, Working Committee , Multidisciplinary Cancer management Course of the American Society of Clinical Oncology. In past he had been president of the Indian Society of Medical and Pediatric Oncology, Jt Secretary Indian Society of Oncology, Associate Editor Indian journal of Medial and Pediatric Oncology.
His most important present activity includes empowerment of peripheral district hospitals in cancer care. Through this chemotherapy services have been initiated in 51 districts of the state of Madhya Pradesh-Central India. The scheme has already benefit thousands of patients and likely to positively impact cancer care and may serve as lead model for many states and countries.
Dr. Somasundaran Subramaniam
Dr. Subramaniam completed his MBBS from National University of Singapore, internal medicine residency from the University of Hawaii, and oncology fellowship at Stanford University. He currently practices at the Swedish Cancer Institute in Seattle. Dr. Subramaniam has presented scientific papers in national and international meetings, has published a book chapter and several scientific articles in peer-reviewed journals.
Dr. Juan Mejia
Dr. Mejia completed fellowships in Liver Transplant Surgery and Hepatobiliary and Pancreatic Surgery at the University of Pittsburgh. The University of Pittsburgh Medical Center is considered one of the top sites in the country for the management of benign and malignant liver conditions. Dr. Mejia was recruited to Providence Spokane soon after completing his training to start a Liver and Pancreas Surgery service. He has a specific interest in minimally invasive techniques for the management of benign and malignant liver conditions.
Dr. Karie-Lynn Kelly
Dr. Kelly is a board certified Radiation Oncologist with Spokane CyberKnife & Radiation Oncology Center. She graduated from the University of Calgary with an honors degree in Biochemistry before completing her medical degree at the University of Alberta. Dr. Kelly completed a five-year residency program in Radiation Oncology at Queens University in Kingston, Ontario and at the Tom Baker Cancer Center in Calgary, Alberta. Upon completion of her Residency, Dr. Kelly practiced at Mercy Cancer Center in Hot Springs, AR, and the Coeur d’Alene and Post Falls Cancer Centers before joining Spokane Valley Cancer Center.
Dr. Kelly is dedicated to providing patients with the highest quality of care using cutting-edge technology. She is trained in all aspects of Radiation Oncology, including CyberKnife® and TrueBeam Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT), IMRT, IGRT, 3DCRT, electron therapy, and brachytherapy. Dr. Kelly is on the American Society of Therapeutic Radiation Oncology Health Services Research Committee and is involved in national cancer research.